Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

Date
2020
Author
De Giorgi, Ugo
Galsky, Matthew D.
Arranz Arija, Jose Angel
Bamias, Aristotelis
Davis, Ian D.
De Santis, Maria
Kikuchi, Eiji
Garcia-del-Muro, Xavier
Mencinger, Marina
Izumi, Kouji
Panni, Stefano
GÜMÜŞ, MAHMUT
ÖZGÜROĞLU, Mustafa
Kalebasty, Arash Rezazadeh
Park, Se Hoon
Alekseev, Boris
Schutz, Fabio A.
Li, Jian-Ri
Ye, Dingwei
Vogelzang, Nicholas J.
Bernhard, Sandrine
Tayama, Darren
Mariathasan, Sanjeev
Mecke, Almut
Thastrom, AnnChristine
Grande, Enrique
Metadata
Show full item record
Abstract
Background Atezolizumab can induce sustained responses in metastatic urothelial carcinoma. We report the results of IMvigor130, a phase 3 trial that compared atezolizumab with or without platinum-based chemotherapy versus placebo plus platinum-based chemotherapy in first-line metastatic urothelial carcinoma.
URI
http://hdl.handle.net/20.500.12627/5056
https://doi.org/10.1016/s0140-6736(20)30230-0
Collections